Research & Literature

Spontaneous activity in electromyography may differentiate certain benign lower motor neuron disease forms from amyotrophic lateral sclerosis.

Jokela ME, Jääskeläinen SK, Sandell S, et al.

Journal of the neurological sciences 2015; (355(1-2)):143-6.

Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview.

Petracca M, Guidubaldi A, Ricciardi L, et al.

Toxicon : official journal of the International Society on Toxinology 2015; (107(Pt A)):129-40.

Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis.

Paganoni S, Karam C, Joyce N, et al.

NeuroRehabilitation 2015; (37(1)):53-68 doi:10.3233/NRE-151240.

Amyotrophic Lateral Sclerosis: New Perpectives and Update.

Orsini M, Oliveira AB, Nascimento OJ, et al.

Neurology international 2015; (7(2)):5885 doi:10.4081/ni.2015.5885.

Progressive Muscular Atrophy.

Liewluck T, Saperstein DS

Neurologic clinics 2015; (33(4)):761-73.

Pulmonary scintigraphy as a method to investigate gastrobronchial communication in tracheostomized patients.

Graziani A, Martelli A, Quercia O, et al.

Respiratory medicine case reports 2015; (16()):29-31 doi:10.1016/j.rmcr.2015.05.015.

Current Therapy of Drugs in Amyotrophic Lateral Sclerosis.

Lu H, Le WD, Xie YY, Wang XP

Current neuropharmacology 2016; (14(4)):314-21 doi:10.2174/1570159x14666160120152423.

A look into the future of ALS research.

Clerc P, Lipnick S, Willett C

Drug discovery today 2016; (21(6)):939-49.

Therapeutic Approach of a High Functioning Individual With Traumatic Brain Injury and Subsequent Emotional Volatility With Features of Pathological Laughter and Crying With Dextromethorphan/Quinidine.

Garcia-Baran D, Johnson TM, Wagner J, et al.

Medicine 2016; (95(12)):e2886 doi:10.1097/MD.0000000000002886.

Lower motor neuron dysfunction in ALS.

de Carvalho M, Swash M

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2016; (127(7)):2670-81.

Announcement: Amyotrophic Lateral Sclerosis (ALS) Awareness Month - May 2016.

MMWR. Morbidity and mortality weekly report 2016; (65(16)):427 doi:10.15585/mmwr.mm6516a6.

Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study.

Ferraro D, Consonni D, Fini N, et al.

European journal of neurology 2016; (23(9)):1426-32 doi:10.1111/ene.13053.

PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.

Hammond FM, Alexander DN, Cutler AJ, et al.

BMC neurology 2016; (16()):89 doi:10.1186/s12883-016-0609-0.

Motor cortical function determines prognosis in sporadic ALS.

Shibuya K, Park SB, Geevasinga N, et al.

Neurology 2016; (87(5)):513-20 doi:10.1212/WNL.0000000000002912.

The epidemiology of amyotrophic lateral sclerosis.

Talbott EO, Malek AM, Lacomis D

Handbook of clinical neurology 2016; (138()):225-38.

The concept and diagnostic criteria of primary lateral sclerosis.

Wais V, Rosenbohm A, Petri S, et al.

Acta neurologica Scandinavica 2017; (136(3)):204-211 doi:10.1111/ane.12713.

Gastrostomy tube placement is safe in advanced amyotrophic lateral sclerosis.

Kak M, Issa NP, Roos RP, et al.

Neurological research 2017; (39(1)):16-22 doi:10.1080/01616412.2016.1259028.

Comparison of the King's and MiToS staging systems for ALS.

Fang T, Al Khleifat A, Stahl DR, et al.

Amyotrophic lateral sclerosis & frontotemporal degeneration 2017; (18(3-4)):227-232 doi:10.1080/21678421.2016.1265565.

Amyotrophic lateral sclerosis or not: Keys for the diagnosis.

Lenglet T, Camdessanché JP

Revue neurologique 2017; (173(5)):280-287 doi:10.1016/j.neurol.2017.04.003.

Supportive care needs of patients with amyotrophic lateral sclerosis/motor neuron disease and their caregivers: A scoping review.

Oh J, Kim JA

Journal of clinical nursing 2017; (26(23-24)):4129-4152 doi:10.1111/jocn.13945.

Patterns of symptom development in patients with motor neuron disease.

Walhout R, Verstraete E, van den Heuvel MP, et al.

Amyotrophic lateral sclerosis & frontotemporal degeneration 2018; (19(1-2)):21-28 doi:10.1080/21678421.2017.1386688.

CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions.

Mehta P, Horton DK, Kasarskis EJ, et al.

MMWR. Morbidity and mortality weekly report 2017; (66(50)):1379-1382 doi:10.15585/mmwr.mm6650a3.

Prevalence of Amyotrophic Lateral Sclerosis - United States, 2014.

Mehta P, Kaye W, Raymond J, et al.

MMWR. Morbidity and mortality weekly report 2018; (67(7)):216-218 doi:10.15585/mmwr.mm6707a3.

[The review of questionnaires and scales evaluating patients with amyotrophic lateral sclerosis].

Bužgová R, Kozáková R, Zeleníková R, Sikorová L

Casopis lekaru ceskych 2018; (157(1)):41-45.

X-linked spinal and bulbar muscular atrophy (Kennedy's disease): the first case described in the Brazilian Amazon.

Alves CN, Braga TKK, Somensi DN, et al.

Einstein (Sao Paulo, Brazil) 2018; (16(2)):eRC4011 doi:10.1590/S1679-45082018RC4011.

Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis.

Gille B, De Schaepdryver M, Goossens J, et al.

Neuropathology and applied neurobiology 2019; (45(3)):291-304 doi:10.1111/nan.12511.

Edaravone: a new hope for deadly amyotrophic lateral sclerosis.

Bhandari R, Kuhad A, Kuhad A

Drugs of today (Barcelona, Spain : 1998) 2018; (54(6)):349-360 doi:10.1358/dot.2018.54.6.2828189.

Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach.

Thakore NJ, Lapin BR, Kinzy TG, Pioro EP

Amyotrophic lateral sclerosis & frontotemporal degeneration 2018; (19(7-8)):483-494 doi:10.1080/21678421.2018.1484925.

Prevalence of Amyotrophic Lateral Sclerosis - United States, 2015.

Mehta P, Kaye W, Raymond J, et al.

MMWR. Morbidity and mortality weekly report 2018; (67(46)):1285-1289 doi:10.15585/mmwr.mm6746a1.

Diagnostic criteria for amyotrophic lateral sclerosis: A multicentre study of inter-rater variation and sensitivity.

Johnsen B, Pugdahl K, Fuglsang-Frederiksen A, et al.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2019; (130(2)):307-314 doi:10.1016/j.clinph.2018.11.021.

Diagnosis Particularities of Amyotrophic Lateral Sclerosis in an Elderly Patient.

Marcu IR, Patru S, Bighea AC

Current health sciences journal 2018; (44(1)):92-96 doi:10.12865/CHSJ.44.01.16.

A standard operating procedure for King's ALS clinical staging.

Balendra R, Al Khleifat A, Fang T, Al-Chalabi A

Amyotrophic lateral sclerosis & frontotemporal degeneration 2019; (20(3-4)):159-164 doi:10.1080/21678421.2018.1556696.

Sialorrhea in patients with ALS: current treatment options.

Garuti G, Rao F, Ribuffo V, Sansone VA

Degenerative neurological and neuromuscular disease 2019; (9()):19-26 doi:10.2147/DNND.S168353.

Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis.

Abu-Rumeileh S, Vacchiano V, Zenesini C, et al.

Journal of neurology 2020; (267(6)):1699-1708 doi:10.1007/s00415-020-09761-z.

Amyotrophic Lateral Sclerosis Modifiers in Drosophila Reveal the Phospholipase D Pathway as a Potential Therapeutic Target.

Kankel MW, Sen A, Lu L, et al.

Genetics 2020; (215(3)):747-766 doi:10.1534/genetics.119.302985.

The Role of Radiation Therapy and Botulinum Toxin Injections in the Management of Sialorrhea in Patients With Amyotrophic Lateral Sclerosis: A Systematic Review.

Shehee L, O'Rourke A, Garand KL

Journal of clinical neuromuscular disease 2020; (21(4)):205-221 doi:10.1097/CND.0000000000000273.

Efficacy of Botulinum Toxin for Treating Sialorrhea in Neuromuscular Conditions.

Singh H, Nene Y, Mehta TR, Govindarajan R

Frontiers in neurology 2020; (11()):513 doi:10.3389/fneur.2020.00513.

P2X7 Receptor Antagonism as a Potential Therapy in Amyotrophic Lateral Sclerosis.

Ruiz-Ruiz C, Calzaferri F, García AG

Frontiers in molecular neuroscience 2020; (13()):93 doi:10.3389/fnmol.2020.00093.

Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.

Miller T, Cudkowicz M, Shaw PJ, et al.

The New England journal of medicine 2020; (383(2)):109-119 doi:10.1056/NEJMoa2003715.

Autophagy and Motor Neuron Diseases.

Zhang X, Yang K, Le W

Advances in experimental medicine and biology 2020; (1207()):53-74 doi:10.1007/978-981-15-4272-5_3.

Novel Selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis.

Amporndanai K, Rogers M, Watanabe S, et al.

EBioMedicine 2020; (59()):102980 doi:10.1016/j.ebiom.2020.102980.

Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.

Paganoni S, Macklin EA, Hendrix S, et al.

The New England journal of medicine 2020; (383(10)):919-930 doi:10.1056/NEJMoa1916945.

Squamous cell carcinoma of the base of the tongue mimicking bulbar-onset amyotrophic lateral sclerosis.

Lin HP, Lieberman L, Patel M, Chuquilin M

Heliyon 2020; (6(8)):e04769 doi:10.1016/j.heliyon.2020.e04769.

Electrodiagnosis of Amyotrophic Lateral Sclerosis: A Review of Existing Guidelines.

de Carvalho M

Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society 2020; (37(4)):294-298 doi:10.1097/WNP.0000000000000682.

Is the ALS a motor neuron disease or a hematopoietic stem cell disease?

Bryukhovetskiy AS, Grivtsova LY, Sharma HS

Progress in brain research 2020; (258()):381-396 doi:10.1016/bs.pbr.2020.09.005.

Pathogenic Genome Signatures That Damage Motor Neurons in Amyotrophic Lateral Sclerosis.

Yousefian-Jazi A, Seol Y, Kim J, et al.

Cells 2020; (9(12)) doi:10.3390/cells9122687.

The cutaneous silent period in motor neuron disease.

Castro J, Swash M, de Carvalho M

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2021; (132(2)):660-665 doi:10.1016/j.clinph.2020.10.033.

Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis.

Cho H, Shukla S

Pharmaceuticals (Basel, Switzerland) 2020; (14(1)) doi:10.3390/ph14010029.

Multidisciplinary care in Amyotrophic Lateral Sclerosis: a systematic review and meta-analysis.

de Almeida FEO, do Carmo Santana AK, de Carvalho FO

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(3)):911-923 doi:10.1007/s10072-020-05011-2.

Spreading of TDP-43 pathology via pyramidal tract induces ALS-like phenotypes in TDP-43 transgenic mice.

Ding X, Xiang Z, Qin C, et al.

Acta neuropathologica communications 2021; (9(1)):15 doi:10.1186/s40478-020-01112-3.

Glial Cell Dysfunction in C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.

Ghasemi M, Keyhanian K, Douthwright C

Cells 2021; (10(2)) doi:10.3390/cells10020249.

Motor Neuron Disease in a Patient With Cervical Spondylotic Myelopathy: Too Much Bad Luck.

Robles LA, Chakravarthy V

Cureus 2021; (13(1)):e12523 doi:10.7759/cureus.12523.

Neurophysiological features of primary lateral sclerosis.

de Carvalho M, Kiernan MC, Pullman SL, et al.

Amyotrophic lateral sclerosis & frontotemporal degeneration 2020; (21(sup1)):11-17 doi:10.1080/21678421.2020.1837174.

Emerging role of microRNAs in the pathogenesis of amyotrophic lateral sclerosis.

Akbari Dilmaghani N, Hussen BM, Nateghinia S, et al.

Metabolic brain disease 2021; (36(5)):737-749 doi:10.1007/s11011-021-00697-5.

The utility of ALS staging systems in a multi-ethnic patient cohort.

Abdul Aziz NA, Toh TH, Loh EC, et al.

Amyotrophic lateral sclerosis & frontotemporal degeneration 2021; (22(5-6)):341-349 doi:10.1080/21678421.2021.1893336.

Upper and Lower Motor Neuron Degenerations Are Somatotopically Related and Temporally Ordered in the Sod1 Mouse Model of Amyotrophic Lateral Sclerosis.

Marques C, Burg T, Scekic-Zahirovic J, et al.

Brain sciences 2021; (11(3)) doi:10.3390/brainsci11030369.

Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study.

Kjældgaard AL, Pilely K, Olsen KS, et al.

BMC neurology 2021; (21(1)):164 doi:10.1186/s12883-021-02187-8.

Awaji criteria for the diagnosis of amyotrophic lateral sclerosis in Hanoi, Vietnam.

Van Nguyen T, Tran TA, Vu HT

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2022; (43(1)):393-398 doi:10.1007/s10072-021-05333-9.

Milano-Torino Staging and Long-Term Survival in Chinese Patients with Amyotrophic Lateral Sclerosis.

He R, Zheng M, Lian L, Yao X

Cells 2021; (10(5)) doi:10.3390/cells10051220.

Percutaneous gastrostomy in amyotrophic lateral sclerosis: a review.

Castanheira A, Swash M, De Carvalho M

Amyotrophic lateral sclerosis & frontotemporal degeneration 2022; (23(3-4)):176-189 doi:10.1080/21678421.2021.1946089.

The Gold Coast criteria increases the diagnostic sensitivity for amyotrophic lateral sclerosis in a Chinese population.

Shen D, Yang X, Wang Y, et al.

Translational neurodegeneration 2021; (10(1)):28 doi:10.1186/s40035-021-00253-2.

Oxidative Stress as a Therapeutic Target in Amyotrophic Lateral Sclerosis: Opportunities and Limitations.

Park HR, Yang EJ

Diagnostics (Basel, Switzerland) 2021; (11(9)) doi:10.3390/diagnostics11091546.

Electrodiagnostic Assessment of Motor Neuron Disease.

Kang X, Quan D

Neurologic clinics 2021; (39(4)):1071-1081 doi:10.1016/j.ncl.2021.06.008.

SIMpLE: A Mobile Cloud-Based System for Health Monitoring of People with ALS.

Palumbo A, Ielpo N, Calabrese B, et al.

Sensors (Basel, Switzerland) 2021; (21(21)) doi:10.3390/s21217239.

Neurofilament markers in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

Shi J, Qin X, Chang X, et al.

Journal of cellular and molecular medicine 2022; (26(2)):583-587 doi:10.1111/jcmm.17100.

Prevalence of Sialorrhea Among Amyotrophic Lateral Sclerosis Patients: A Systematic Review and Meta-Analysis.

Wang Y, Yang X, Han Q, et al.

Journal of pain and symptom management 2022; (63(4)):e387-e396 doi:10.1016/j.jpainsymman.2021.12.005.

Motor neuron replacement therapy for amyotrophic lateral sclerosis.

Liu B, Li M, Zhang L, et al.

Neural regeneration research 2022; (17(8)):1633-1639 doi:10.4103/1673-5374.332123.

Atypical Familial Amyotrophic Lateral Sclerosis Secondary to Superoxide Dismutase 1 Gene Mutation With Coexistent Axonal Polyneuropathy: A Challenging Diagnosis.

Makkawi S, Alqarni AA, Alghaythee H, et al.

Cureus 2022; (14(1)):e20989 doi:10.7759/cureus.20989.

Ultrasonographic evaluation reveals thinning of cervical nerve roots and peripheral nerves in spinal and bulbar muscular atrophy.

Watanabe D, Tsukamoto H, Abe T, et al.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2022; (43(7)):4267-4274 doi:10.1007/s10072-022-05969-1.

[Cramps and fasciculations: is it amyotrophic lateral sclerosis?]

Hübers A, Fayolle D, Ochsner F, et al.

Revue medicale suisse 2022; (18(779)):790-793 doi:10.53738/REVMED.2022.18.779.790.

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.

James E, Ellis C, Brassington R, et al.

The Cochrane database of systematic reviews 2022; (5()):CD006981 doi:10.1002/14651858.CD006981.pub3.

Gold Coast criteria expand clinical trial eligibility in amyotrophic lateral sclerosis.

Jewett G, Khayambashi S, Frost GS, et al.

Muscle & nerve 2022; (66(4)):397-403 doi:10.1002/mus.27660.

Ethnical Disparities in Response to Edaravone in Patients With Amyotrophic Lateral Sclerosis.

Jayasinghe M, Jena R, Singhal M, et al.

Cureus 2022; (14(6)):e25960 doi:10.7759/cureus.25960.

A systematic review of digital technology to evaluate motor function and disease progression in motor neuron disease.

Beswick E, Fawcett T, Hassan Z, et al.

Journal of neurology 2022; (269(12)):6254-6268 doi:10.1007/s00415-022-11312-7.

Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.

Miller TM, Cudkowicz ME, Genge A, et al.

The New England journal of medicine 2022; (387(12)):1099-1110 doi:10.1056/NEJMoa2204705.

Synaptic dysfunction in ALS and FTD: anatomical and molecular changes provide insights into mechanisms of disease.

Gelon PA, Dutchak PA, Sephton CF

Frontiers in molecular neuroscience 2022; (15()):1000183 doi:10.3389/fnmol.2022.1000183.

Riluzole and Edavarone: The Hope Against Amyotrophic Lateral Sclerosis.

Rokade AV, Yelne P, Giri A

Cureus 2022; (14(10)):e30035 doi:10.7759/cureus.30035.

Split phenomena in amyotrophic lateral sclerosis: Current evidences, pathogenetic hypotheses and diagnostic implications.

Zoccolella S, Giugno A, Logroscino G

Frontiers in neuroscience 2022; (16()):1100040 doi:10.3389/fnins.2022.1100040.

An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.

Sun Y, Li X, Bedlack R

Expert review of neurotherapeutics 2023; (23(1)):1-7 doi:10.1080/14737175.2023.2174018.

The Muscular Dystrophy Association's neuroMuscular ObserVational Research Data Hub (MOVR): Design, Methods, and Initial Observations.

Kilroy EA, Burris R, Javelosa E, et al.

Journal of neuromuscular diseases 2023; (10(3)):365-380 doi:10.3233/JND-221551.

Serum neurofilament light chain cut-off definition for clinical diagnosis and prognosis of amyotrophic lateral sclerosis.

Brousse M, Delaby C, De La Cruz E, et al.

European journal of neurology 2023; (30(7)):1919-1927 doi:10.1111/ene.15813.

Motor Band Sign in Primary Lateral Sclerosis: A Case Report Proposing the Need for an Imaging Biomarker.

Valaparla VL, Lobaina M, Patel C, Patel AV

Cureus 2023; (15(3)):e36121 doi:10.7759/cureus.36121.

MicroRNA-23a-3p Is Upregulated in Plasma Exosomes of Bulbar-onset ALS Patients and Targets ERBB4.

Liu Y, Ding M, Pan S, et al.

Neuroscience 2023; (524()):65-78 doi:10.1016/j.neuroscience.2023.05.030.

Serum Neurofilaments in Motor Neuron Disease and Their Utility in Differentiating ALS, PMA and PLS.

McCluskey G, Morrison KE, Donaghy C, et al.

Life (Basel, Switzerland) 2023; (13(6)) doi:10.3390/life13061301.

ALSUntangled #71: Nuedexta.

Sun Y, Benatar M, Mascías Cadavid J, et al.

Amyotrophic lateral sclerosis & frontotemporal degeneration 2024; (25(1-2)):218-222 doi:10.1080/21678421.2023.2239292.

Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease.

Sulistyo A, Abrahao A, Freitas ME, et al.

The Cochrane database of systematic reviews 2023; (8()):CD004030 doi:10.1002/14651858.CD004030.pub4.

Management of amyotrophic lateral sclerosis in clinical practice: Results of the expert consensus using the Delphi methodology.

Cassereau J, Bernard E, Genestet S, et al.

Revue neurologique 2023; (179(10)):1134-1144 doi:10.1016/j.neurol.2023.07.011.

Defining conditions for effective interdisciplinary care team communication in an open surgical intensive care unit: a qualitative study.

Diaz CM, Egide A, Berry A, et al.

BMJ open 2023; (13(12)):e075470 doi:10.1136/bmjopen-2023-075470.

Role of C9orf72 hexanucleotide repeat expansions in ALS/FTD pathogenesis.

Geng Y, Cai Q

Frontiers in molecular neuroscience 2024; (17()):1322720 doi:10.3389/fnmol.2024.1322720.

Timing and impact of percutaneous endoscopic gastrostomy insertion in patients with amyotrophic lateral sclerosis: a comprehensive analysis.

Son B, Lee J, Ryu S, et al.

Scientific reports 2024; (14(1)):7103 doi:10.1038/s41598-024-56752-5.

Optimizing breathlessness management in amyotrophic lateral sclerosis: insights from a comprehensive systematic review.

Filipe CB, Carreira NR, Reis-Pina P

BMC palliative care 2024; (23(1)):100 doi:10.1186/s12904-024-01429-z.

A single ALS center experience with clinical use of sodium phenylbutyrate-taurursodiol.

Quinn C, Baer M, Amado DA, et al.

Muscle & nerve 2024; (70(1)):148-151 doi:10.1002/mus.28096.

Categorization of the amyotrophic lateral sclerosis population via the clinical determinant of post-onset ΔFS for study design and medical practice.

Ludolph AC, Corcia P, Desnuelle C, et al.

Muscle & nerve 2024; (70(1)):36-41 doi:10.1002/mus.28101.

Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.

Oliveira Santos M, de Carvalho M

Expert review of neurotherapeutics 2024; (24(6)):549-553 doi:10.1080/14737175.2024.2355983.

Amyotrophic lateral sclerosis; clinical features, differential diagnosis and pathology.

Van Es MA

International review of neurobiology 2024; (176()):1-47 doi:10.1016/bs.irn.2024.04.011.

Updates on Disease Mechanisms and Therapeutics for Amyotrophic Lateral Sclerosis.

Nguyen L

Cells 2024; (13(11)) doi:10.3390/cells13110888.

Sodium Phenylbutyrate and Tauroursodeoxycholic Acid: A Story of Hope Turned to Disappointment in Amyotrophic Lateral Sclerosis Treatment.

Ketabforoush A, Faghihi F, Azedi F, et al.

Clinical drug investigation 2024; (44(7)):495-512 doi:10.1007/s40261-024-01371-1.

Diagnostic criteria for amyotrophic lateral sclerosis.

Timmins HC, Thompson AE, Kiernan MC

Current opinion in neurology 2024; (37(5)):570-576 doi:10.1097/WCO.0000000000001302.

Ultra-high dose methylcobalamin and other emerging therapies for amyotrophic lateral sclerosis.

Kaji R, Izumi Y, Oki R

Current opinion in neurology 2024; (37(5)):593-602 doi:10.1097/WCO.0000000000001311.

Unraveling the multifaceted insights into amyotrophic lateral sclerosis: Genetic underpinnings, pathogenesis, and therapeutic horizons.

Sharma R, Khan Z, Mehan S, et al.

Mutation research. Reviews in mutation research 2024; (794()):108518 doi:10.1016/j.mrrev.2024.108518.

[Gold Coast Criteria: A New Diagnostic Paradigm in the Era of Disease-Modifying Therapy for Amyotrophic Lateral Sclerosis].

Yamakawa I, Urushitani M

Brain and nerve = Shinkei kenkyu no shinpo 2024; (76(11)):1217-1223 doi:10.11477/mf.1416202763.

Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapies.

A Virata MC, Catahay JA, Lippi G, Henry BM

Neurodegenerative disease management 2024; (14(6)):227-239 doi:10.1080/17582024.2024.2421738.

Integrating Multi-sensor Time-series Data for ALSFRS-R Clinical Scale Predictions in an ALS Patient Case Study.

Marchal N, Janes WE, Earwood JH, et al.

AMIA ... Annual Symposium proceedings. AMIA Symposium 2024; (2024()):788-797.

Tofersen: A Review in Amyotrophic Lateral Sclerosis Associated with SOD1 Mutations.

McGuigan A, Blair HA

CNS drugs 2025; (39(9)):903-912 doi:10.1007/s40263-025-01204-5.

Real-World Clinical Experience With Sodium Phenylbutyrate and Taurursodiol at a Single Amyotrophic Lateral Sclerosis Center in the United States.

Calcagno N, Scirocco E, Clampffer E, et al.

European journal of neurology 2025; (32(9)):e70360 doi:10.1111/ene.70360.

Tongue shear wave elastography for bulbar dysfunction in amyotrophic lateral sclerosis.

Yanagawa K, Ike M, Aoyama A, et al.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2025; (179()):2111367 doi:10.1016/j.clinph.2025.2111367.

Correlations of cerebrospinal fluid neurofilament light chain levels with clinical and electromyography findings in amyotrophic lateral sclerosis.

Matur Z, Deveci Ş, Erdal Y

Irish journal of medical science 2025; doi:10.1007/s11845-025-04209-7.

Efficacy and safety of dextromethorphan/quinidine in treating pseudobulbar affect in neurological disorders: A systematic review and dose-classified network meta-analysis.

Muneer MA, Tariq I, Zulfiqar E, et al.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026; (47(1)):159.

Meeting report: 2024 Muscular Dystrophy Association summit on 'Safety and challenges in gene therapy of neuromuscular diseases'.

Lek A, Atas E, Lin B, et al.

Journal of neuromuscular diseases 2026; 22143602251364325 doi:10.1177/22143602251364325.

The Potential Misdiagnosis of Multifocal Motor Neuropathy as Amyotrophic Lateral Sclerosis-A Case Series.

Lawson V, Robbins NM

US neurology 2018; (14(2)):102-107 doi:10.17925/usn.2018.14.2.102.

Tofersen: A Novel Option for the Treatment of Amyotrophic Lateral Sclerosis.

Karros M, DiFulco M, Nogid A

The Annals of pharmacotherapy 2026; 10600280251408862 doi:10.1177/10600280251408862.

Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis.

Miller TM, Cudkowicz ME, Shaw PJ, et al.

JAMA neurology 2026; (83(2)):115-125 doi:10.1001/jamaneurol.2025.4946.